ClinicalTrialsFinder

RecruitingPhase 2NCT07415031

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)

Sponsor

Mirati Therapeutics Inc.

Enrollment

170 participants

Start Date

May 6, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.

Exclusion Criteria3

Participant is not eligible for study treatment per the parent study eligibility criteria.
Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study.
Participants not receiving clinical benefit from parent study drug as assessed by the investigator.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAdagrasib

Specified dose on specified days

DRUGPembrolizumab

Specified dose on specified days

DRUGCetuximab

Specified dose on specified days

DRUGPemetrexed

Specified dose on specified days

DRUGDocetaxel

Specified dose on specified days

DRUGIrinotecan

Specified dose on specified days

DRUGLeucovorin

Specified dose on specified days

DRUGOxaliplatin

Specified dose on specified days

DRUGFluorouracil

Specified dose on specified days

Locations(77)

Local Institution - 0005

Phoenix, Arizona, United States

Local Institution - 0016

Bellflower, California, United States

Local Institution - 0082

Long Beach, California, United States

Local Institution - 0003

Newark, Delaware, United States

Local Institution - 0001

St. Petersburg, Florida, United States

Local Institution - 0064

Chicago, Illinois, United States

Local Institution - 0112

Wichita, Kansas, United States

Local Institution - 0092

Boston, Massachusetts, United States

Local Institution - 0080

Boston, Massachusetts, United States

Mayo Clinic in Rochester, Minnesota

Rochester, Minnesota, United States

Local Institution - 0073

Saint Paul, Minnesota, United States

Local Institution - 0036

Omaha, Nebraska, United States

Local Institution - 0116

New York, New York, United States

Local Institution - 0004

Eugene, Oregon, United States

Local Institution - 0023

Germantown, Tennessee, United States

Local Institution - 0002

Grapevine, Texas, United States

Local Institution - 0013

Bellingham, Washington, United States

Local Institution - 0093

St Leonards, New South Wales, Australia

Local Institution - 0033

Ghent, Belgium

Local Institution - 0072

Vancouver, British Columbia, Canada

Local Institution - 0076

Nice, Alpes-Maritimes, France

Local Institution - 0103

Pessac, Aquitaine, France

Local Institution - 0058

Quimper, Brittany Region, France

Local Institution - 0032

Angers, Maine-et-Loire, France

Local Institution - 0075

Gleizé, Rhône, France

Local Institution - 0091

Besançon, France

Local Institution - 0090

Bron, France

Local Institution - 0085

Créteil, France

Local Institution - 0065

Grenoble, France

Local Institution - 0059

Marseille, France

Local Institution - 0086

Nice, France

Local Institution - 0051

Poitiers, France

Local Institution - 0063

Saint-Herblain, France

Local Institution - 0050

Saint-Herblain, France

Local Institution - 0078

Saint-Mandé, France

Local Institution - 0074

Strasbourg, France

Local Institution - 0077

Tours, France

Local Institution - 0061

Paris, Île-de-France Region, France

Local Institution - 0012

München, Germany

Local Institution - 0081

Athens, Attikí, Greece

Local Institution - 0022

Attiki, Greece

Local Institution - 0087

Thessaloniki, Greece

Local Institution - 0055

Jerusalem, Jerusalem, Israel

Local Institution - 0057

Tel Aviv, Tel Aviv, Israel

Local Institution - 0106

Tel Aviv, Israel

Local Institution - 0019

Rome, Roma, Italy

Local Institution - 0053

Bologna, Italy

Local Institution - 0054

Florence, Italy

Local Institution - 0052

Meldola, Italy

Local Institution - 0021

Milan, Italy

Local Institution - 0107

Milan, Italy

Local Institution - 0020

Orbassano, Italy

Local Institution - 0079

Pesaro, Italy

Local Institution - 0031

Roma, Italy

Local Institution - 0026

Terni (Perugia), Italy

Local Institution - 0056

Breda, North Brabant, Netherlands

Local Institution - 0034

Amsterdam, Netherlands

Local Institution - 0035

Harderwijk, Netherlands

Local Institution - 0071

Utrecht, Netherlands

Local Institution - 0014

Lisbon, Lisbon District, Portugal

Local Institution - 0060

Craiova, Dolj, Romania

Local Institution - 0088

Singapore, Central Singapore, Singapore

Local Institution - 0007

A Coruña, A Coruña [La Coruña], Spain

Local Institution - 0011

Palma, Balears [Baleares], Spain

Local Institution - 0010

Barcelona, Barcelona [Barcelona], Spain

Local Institution - 0006

Badalona, Barcelona, Spain

Local Institution - 0030

Santander, Cantabria, Spain

Local Institution - 0024

Madrid, Madrid, Comunidad de, Spain

Local Institution - 0009

Pamplona, Navarre, Spain

Local Institution - 0084

Valencia, Valenciana, Comunitat, Spain

Local Institution - 0029

Barcelona, Spain

Local Institution - 0027

Córdoba, Spain

Local Institution - 0083

Madrid, Spain

Local Institution - 0015

Madrid, Spain

Local Institution - 0062

Madrid, Spain

Local Institution - 0018

Málaga, Spain

Local Institution - 0008

Seville, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT07415031

Related Trials

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873780 locations

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT0550379769 locations

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

NCT060664241 location

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

NCT0515533240 locations

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

NCT0718168113 locations